LunaVax Insights

LunaVax Insights: Measles is Spreading Again in the US

More than 4,000 cases: When coverage slips. The United States declared measles eliminated in 2000. In 2026, it is spreading again. According to the Centers for Disease Control and Prevention (CDC), the US has reported more than 4,000 confirmed measles cases this year, with 42 new outbreaks across the country. Nearly all cases are linked

LunaVax Insights: Measles is Spreading Again in the US Read More »

LunaVax Insights: Nigeria Launches Africa’s Largest Vaccination Campaign

A historic national effort. Nigeria has launched Africa’s largest integrated health campaign, targeting nearly 100 million children with life-saving vaccines and treatments. From measles-rubella and HPV to polio, routine childhood vaccines, NTD interventions, and malaria SMC, this coordinated nationwide push aims to close long-standing immunity gaps across all 36 states. The campaign is rolling out

LunaVax Insights: Nigeria Launches Africa’s Largest Vaccination Campaign Read More »

The LunaVax Advisory Board: Guiding our Planned Phase III MR-MAP Work

As LunaVax prepares for its planned Phase III measles-rubella microarray patch (MR-MAP) effectiveness-implementation trial in Nigeria, our Advisory Board provides expert guidance across clinical research, regulatory science, implementation science, digital health, policy and financing. The LunaVax Advisory Board brings together leaders across clinical research, regulatory science, implementation science, digital health, policy and financing to support

The LunaVax Advisory Board: Guiding our Planned Phase III MR-MAP Work Read More »

LunaVax Insights: Biometrics for Vaccine Equity in Ghana

Biometrics that count. In Ghana, frontline health workers are using Simprints’ biometric technology to make sure vaccines reach the child they are meant for. By linking each patient to a unique digital identity, no dose is wasted, no record is lost, and no child is overlooked. For health systems facing challenges of duplication, misidentification, and

LunaVax Insights: Biometrics for Vaccine Equity in Ghana Read More »

LunaVax Insights: Nigeria sustains WHO milestone for vaccine production

A first for Africa: Nigeria sustains WHO’s ML3 status. In August 2025, Nigeria became the first country in Africa to successfully sustain the World Health Organization’s Maturity Level 3 (ML3) for regulating medicines and vaccines. This milestone affirms the strength of Nigeria’s regulatory system, a key foundation for safe local vaccine production and reduced dependence

LunaVax Insights: Nigeria sustains WHO milestone for vaccine production Read More »

LunaVax Insights: Microneedle Patches and the Future of Vaccine Access

Needle-free. Closer to communities. In Nigeria and other regions where distance and infrastructure limit access, microneedle vaccine patches (MAPs) could bring vaccines closer to the people who need them most. MAPs are an emerging, needle-free vaccine delivery method designed to be easy to apply and more heat-stable than conventional vaccines, reducing dependence on the cold

LunaVax Insights: Microneedle Patches and the Future of Vaccine Access Read More »

LunaVax Insights: Drone-Powered Vaccine Access in Nigeria

20,000 vaccine deliveries. No roads required. In Bayelsa, Nigeria, malaria vaccines are now reaching hard-to-reach communities by air. A Gavi-backed initiative, in partnership with Zipline, is delivering hope—one drone drop at a time—where traditional health delivery can’t go. At LunaVax, we spotlight bold solutions advancing last-mile vaccine access. From drones today to microneedle patches tomorrow,

LunaVax Insights: Drone-Powered Vaccine Access in Nigeria Read More »